Loading news...
In the fourth quarter, Revolve's stock rose as its revenue met expectations with a 4.4% year-over-year increase. In fiscal second quarter 2026, Haemonetics delivered strong performance, raising guidance and posting margin gains that signal operational discipline. CHWY shares declined in September after the company reported elevated selling, general, and administrative expenses.
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.
Cwm LLC lessened its holdings in Bruker Corporation (NASDAQ: BRKR) by 98.1% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,089 shares of the medical research company's stock after selling 55,842 shares during the quarter. Cwm LLC's holdings in Bruker were
Bruker Corporation (NASDAQ: BRKR - Get Free Report) VP Mark Munch sold 2,000 shares of the firm's stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $49.20, for a total transaction of $98,400.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at
Bruker (NASDAQ: BRKR) executives used a conference presentation and Q&A session to outline what they described as an "incremental evolutionary" update for 2026, following a challenging 2025. Management emphasized a shift toward profitability and recurring revenue while continuing to invest in post-genomic discovery tools and expanding its "Project Accelerate" program into a third iteration. Focus shifts
Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bruker BEST division announced $500M supply deals with global radiology companies for advanced superconductors used in MRI magnets.
HANAU, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker's latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe.
Bruker is positioned for strong FY26 growth, driven by backlog, end-market recovery, and high-margin semiconductor orders. BRKR should see margin expansion from cost reductions, improved pricing, favorable mix, and easing M&A-related dilution. The stock trades at a significant discount to historical and peer valuations, despite expectations of double-digit EPS growth from FY26 onward.
THUN, Switzerland--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of an additional 60% ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100%. The transaction adds ultra-fast TOF-MS technology for small-molecule markets, including atmospheric chemistry research, air quality monitoring, exposomics, foods, flavors &a.
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events.
Shares of Bruker Corporation (NASDAQ: BRKR - Get Free Report) have been assigned an average rating of "Hold" from the seventeen brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has given
Bruker Corporation (NASDAQ: BRKR - Get Free Report) passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $39.00 and traded as high as $48.72. Bruker shares last traded at $48.44, with a volume of 1,316,616 shares changing hands. Wall Street Analyst Weigh In BRKR has been
Utah-based Grandeur Peak Global Advisors sold 709,697 shares of Bruker in the third quarter. The estimated position value declined by $29.54 million from the previous period.
Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.
BERGISCH GLADBACH, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--RI Research Instruments, a company that is majority-owned by Bruker Corporation (Nasdaq: BRKR), today announced orders for key components and enabling subsystems for the research gamma ray source of the Extreme Light Infrastructure – Nuclear Physics (ELI-NP) at the Horia Hulubei National Institute of Physics and Nuclear Engineering (IFIN-HH) in Romania. The total value of these ELI contracts is approximately €35 million (more than USD $40 million), w.
Orion Porfolio Solutions LLC decreased its stake in Bruker Corporation (NASDAQ: BRKR) by 40.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 34,487 shares of the medical research company's stock after selling 22,961 shares during the quarter. Orion Porfolio Solutions LLC's holdings
Bruker Corporation (NASDAQ: BRKR - Get Free Report) has been assigned a consensus recommendation of "Hold" from the sixteen brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and one has issued
ETTLINGEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced several significant European orders for high-performance magnetic resonance systems from three leading research institutions in France and Germany: In the summer, École Normale Supérieure (ENS-PSL) in Paris, France ordered a novel NMR relaxometry system to be used alongside its recently acquired 900 MHz NMR spectrometer. This unique capability will empower the investigation of the molecular dynamics of protei.
Bruker Corporation (BRKR) Presents at 53rd Annual Nasdaq Investor Conference Transcript